Actively Recruiting

Age: 37Weeks - 42Weeks
All Genders
NCT07182513

Turkish Version of the Hammersmith Neonatal Neurological Examination (HNNE)

Led by Kahramanmaras Sutcu Imam University · Updated on 2025-09-19

120

Participants Needed

1

Research Sites

29 weeks

Total Duration

On this page

Sponsors

K

Kahramanmaras Sutcu Imam University

Lead Sponsor

G

Gazi University

Collaborating Sponsor

AI-Summary

What this Trial Is About

High-risk infants are defined as an infant with a history of adverse environmental and biological factors that may lead to neuromotor developmental problems. This group includes premature babies born at less than 37 weeks, term babies with low birth weight (LBW), or babies with developmental delays due to various reasons. These babies are also monitored for cerebral palsy (CP). CP is the most common physical disability in childhood, with an incidence of 2.1 per 1000 births. CP encompasses a group of permanent impairments in movement and posture development resulting from injury to the developing brain. Thanks to preventive measures and advances in obstetric and neonatal care, the incidence and severity of CP are currently decreasing in some countries, and it is emphasized that recovery can be more rapid with the use of early diagnosis guidelines or protocols in follow-up units. Early detection and monitoring of infants in the community for CP is essential only with appropriate, valid, and reliable tools to minimize potential sequelae through the timely implementation of CP-specific interventions. International guidelines require monitoring of infants at high risk of CP. This follow-up should be conducted by an interdisciplinary team, including a neonatologist, pediatrician, pediatric neurologist, pediatric physiotherapist, speech-language-swallowing therapist, and special education specialist. Pediatric physiotherapists are an important part of this team for developmental follow-up and rehabilitation. The Hammersmith Neonatal Neurological Examination (HNNE) is a method developed by Dubowitz and used in both clinical and research neurological examinations of preterm and term infants, is the neonatal form of the Hammersmith Infant Neurological Examination (HINE). Its use in the Neonatal Intensive Care Unit (NICU) is crucial for beginning risk assessment as early as possible. Research has determined the optimality score for this test for term infants evaluated in the first days after birth. Subsequently, the current version of the HNNE was standardized by evaluating low-risk term and high-risk preterm infants (25-34 weeks) at term ages, 6-48 hours after birth.The aim of this study was to develop a Turkish version of the HNNE for high-risk infants in Turkey and determine its validity and reliability. The translated HNNE version, which was found to be valid and reliable in this population, will be suitable for use by all healthcare professionals in Turkey. This study also aimed to determine the predictive value of HNNE at corrected 3-4/6 and 12 months when used in the follow-up of at-risk infants in NICUs in Turkey.The study consists of two phases. The first phase consisted of translating the short version of the survey into Turkish and conducting its cultural adaptation. The second phase involved reliability analysis. The principles of Guillemin et al. and Beaton et al. will be used in the translation and cultural adaptation processes.

CONDITIONS

Official Title

Turkish Version of the Hammersmith Neonatal Neurological Examination (HNNE)

Who Can Participate

Age: 37Weeks - 42Weeks
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Infants with periventricular hemorrhage, intracranial hemorrhage grades 2, 3, or 4, cystic periventricular leukomalacia, stage 3 hypoxic ischemic encephalopathy, neonatal bilirubin encephalopathy, perinatal stroke, perinatal asphyxia, or hydrocephalus
  • Infants with chronic lung disease, respiratory distress syndrome, bronchopulmonary dysplasia, or requiring long-term oxygen supplementation
  • Preterm infants with gram-negative bacterial sepsis, necrotizing enterocolitis, or infantile apnea
  • Preterm infants with a 5-minute Apgar score of 3 or below, intrauterine growth restriction, multiple births (twins, triplets), or retinopathy of prematurity
  • Infants with prolonged severe hypoglycemia or hypocalcemia
  • Babies small for gestational age (less than 3rd percentile) or large for gestational age (greater than 97th percentile)
  • Babies who have received mechanical ventilation for more than 24 hours
  • Babies born before 32 weeks of gestation and weighing less than 1500 grams
Not Eligible

You will not qualify if you...

  • Babies with congenital malformations such as spina bifida, congenital muscular torticollis, or arthrogryposis multiplex congenita
  • Babies diagnosed with metabolic or genetic diseases such as Down syndrome, spinal muscular atrophy, or Duchenne muscular dystrophy
  • Babies still intubated and mechanically ventilated at 3 months postterm

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Kahramanmaraş Sütçü imam University

Kahramanmaraş, Onikişubat, Turkey (Türkiye), 46100

Actively Recruiting

Loading map...

Research Team

H

hatice adıgüzel tat, Associate Proffessor

CONTACT

H

hatice Adiguzel tat Associate Proffessor, Pt, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here